Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“However, based on its receptor pharmacology, it is believed that the efficacy of Lurasidone hydrochloride is mediated mainly through antagonist activity at dopamine D 2 and 5-hydroxytryptamine (5- HT, serotonin) 5-HT 2A receptors.”
“Following administration of 40 mg the mean (%CV) elimination half-life was 18 (7) hours.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Based on in vitro studies, lurasidone is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes. Lurasidone is predominantly metabolized by CYP3A4; interaction of Lurasidone hydrochloride with strong and moderate inhibitors or inducers of this enzyme has been observed (Table 5).”